Exocrine Pancreas Carcinoma — Trials

Exocrine Pancreas Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

919 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 358
Recruiting: 209
Ph III recruiting: 23
Growth YoY: +41.4%
Industry share: 41%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (136)

clinicaltrialsPublishedShowing 1–10 of 10 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04083235	A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment(NAPOLI 3)	completed	Phase 3	770	IpsenINDUSTRY	18	Apr 20, 2026	clinicaltrials
NCT01013649	Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery	completed	Phase 3	546	National Cancer Institute (NCI)